BIOLIFE SOLUTIONS INC — Director's Dealing 2023

May 17, 2023

SEC Form 4/A — Form 4/A

Issuer: BIOLIFE SOLUTIONS INC (BLFS)
CIK: 0000834365
Period of Report: 2023-03-31

Reporting Person: Mathew Aby J. (EVP & Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-31	Common Stock	M	4891	—	Acquired	275336	Direct
2023-04-06	Common Stock	S	2093	$20.03	Disposed	273243	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-31	Restricted Stock Award	$0	M	4891	Disposed		Common Stock (4891)	Direct

Footnotes

F1: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F2: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

F3: This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 4,891 shares.